European Lung Cancer Congress

First-line treatment with single-agent osimertinib (Tagrisso) induced a response rate of 77% in patients with EGFR-mutated non–small cell lung cancer.

Thierry Jahan, MD, professor of medicine at the UCSF Helen Diller Family Comprehensive Cancer Center in San Francisco, discusses CRS-20, a live, attenuated Listeria monocytogenes bacterium which is being investigated with chemotherapy in malignant pleural mesothelioma (MPM).

Patients with non-small cell lung cancer who had ceased to respond to EGFR TKI therapy demonstrated a rapid and robust response to the investigational agent BI-1482694 (HM61713).